Neuralink's human clinical trials have generated extraordinary headlines — and extraordinary scrutiny. The company's first human patient, Noland Arbaugh, demonstrated the ability to control a computer cursor and play chess using only neural signals, results that Neuralink shared publicly via livestream in early 2024. Here is an analysis of what the research actually shows, what remains unverified, and the regulatory path ahead.
What Has Been Demonstrated
Neuralink's N1 implant — a coin-sized device containing 1,024 electrodes implanted in the motor cortex — has demonstrated the ability to decode intended movement signals and translate them into computer commands. The first patient, Noland Arbaugh, publicly demonstrated cursor control, web browsing, and gaming using only thought. These demonstrations were conducted live and are verifiable.
The N2 implant, Neuralink's second-generation device, contains significantly more electrodes than the original N1, which in principle allows the system to capture neural signals from a larger area of motor cortex. Higher electrode density generally correlates with higher-bandwidth communication, though the relationship is not linear and depends heavily on signal processing.
What Remains Preliminary
Specific performance figures — such as words-per-minute typing speeds — reported in early coverage should be treated as preliminary. Neuralink has not published peer-reviewed data on its human trial results as of mid-2026. Independent replication of specific performance claims has not yet occurred. The company's trial data is submitted to the FDA as part of its Investigational Device Exemption, but this data is not publicly available.
The speech synthesis capability — generating synthesised speech directly from neural signals — is an active area of research across multiple labs, but remains experimental and not yet reliable enough for daily use in any published system.
The Regulatory Path
Neuralink received FDA Breakthrough Device designation, which is a real and verifiable regulatory status that accelerates the review process for devices that treat serious conditions. This designation does not constitute approval — it means the FDA will work more closely with the company during development. The company is conducting its PRIME Study (Precise Robotically Implanted Brain-Computer Interface) under an FDA Investigational Device Exemption.
The Broader BCI Landscape
Neuralink is not the only company in this space. Synchron, which uses a less invasive endovascular approach, has also conducted human trials and published peer-reviewed results. BrainGate, a research consortium, has published extensively on BCI performance in paralysed patients. The broader research literature provides important context for evaluating any single company's claims.
The Long-Term Vision
Neuralink's stated long-term goal extends beyond medical applications. Elon Musk has described a future where BCIs enable "symbiosis" between humans and AI — a direct neural interface that allows humans to access AI capabilities as naturally as they access their own thoughts. This vision is decades away from technical feasibility, but it shapes the company's research agenda and its public communications.
The more immediate and credible vision is medical: restoring communication and motor function to people with paralysis, ALS, and locked-in syndrome. The first generation of BCI patients — people who have lost the ability to communicate or move — represent the most compelling use case, and the one where the risk-benefit calculation most clearly favours the technology.
What Comes Next
The key milestones to watch over the next 12–24 months: publication of peer-reviewed data from the PRIME Study, which would allow independent assessment of the N1 implant's performance; FDA approval of the N2 implant for expanded trials; and the results of Synchron's competing trials, which will provide a comparison point for evaluating Neuralink's claims. The BCI field is moving quickly, and the next two years will substantially clarify which approaches are viable and which are not.
The Patient Perspective
For the people who stand to benefit most from BCI technology — those with ALS, locked-in syndrome, or severe paralysis — the pace of development is both exciting and frustrating. Noland Arbaugh, Neuralink's first patient, has spoken publicly about how the implant has transformed his daily life, allowing him to browse the internet, play games, and communicate more easily than he could before. His experience represents the human stakes behind the technical debates — and a reminder that for some people, this technology is not a futuristic curiosity but a life-changing medical intervention available today.